Prota/MCRI completes enrolment of Phase 2b multicentre clinical trial of probiotic oral immunotherapy for the treatment of peanut allergy (PPOIT-003) Media ReleaseCarolyn MillerMay 23, 2018Prota Therapeutics, Paul Kelly
Prota Therapeutics partners with world leading bioscience company, Chr. Hansen Media ReleaseCarolyn MillerApril 19, 2018Paul Kelly, Prota Therapeutics, OneVentures
Prota Therapeutics releases data from four year immunotherapy study with outstanding results In the newsCarolyn MillerAugust 21, 2017Prota Therapeutics, Paul Kelly
OneVentures makes first investment for the Biomedical Translation Fund Media ReleaseCarolyn MillerMay 27, 2017Prota Therapeutics, Anne-Marie Birkill, Paul Kelly, Michelle Deaker
Australia’s ProTA accelerates the development of immunotherapy to treat peanut allergy Media ReleaseCarolyn MillerApril 7, 2017Prota Therapeutics, Paul Kelly
